CytoTools AG

Symbol: T5O.DE




Market price today

  • -4.2935

    P/E Ratio

  • 0.0000

    PEG Ratio

  • 2.02M

    MRK Cap

  • 0.00%

    DIV Yield

CytoTools AG (T5O-DE) Stock Price & Analysis

Shares Outstanding


Gross Profit Margin


Operating Profit Margin


Net Profit Margin


Return on Assets


Return on Equity


Return on Capital Employed


Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Dr. Mark-André Freyberg
Full-time employees:1
Address:Klappacher Strasse 126

CytoTools AG, a biotechnology company, develops a pipeline of disease modifying therapies. The company's therapies include proprietary small molecules and biologics to provide treatment options in dermatology, cardiology and angiology, urology, and oncology. Its lead clinical product is DermaPro that has completed Phase III clinical trials for the treatment of diabetic foot ulcers in India; is in Phase III clinical trials for diabetic foot ulcer treatment in Europe; and is in Phase II/III clinical studies for the treatment of venous leg ulcers in Germany, as well as is used as an anti-infective. The company also develops Utisept, an urological medical device for flushing the bladder in urinary tract infections; Derma MP for the treatment of venous leg ulcers in Europe; CardioClean that is in preclinical stage for the treatment of restenosis, diabetis, and carotis-stenosis; and Cancer T17-n for cancer treatment in Europe. CytoTools has collaboration agreement with Activoris Medizintechnik GmbH to develop inhalation therapy for viral infections, such as COVID-19 and influenza. CytoTools AG was founded in 2000 and is based in Darmstadt, Germany.

General Outlook

When we look at how much money they make before expenses, they keep 1.000% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -30.361%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -29.508%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.023% return, is a testament to CytoTools AG's adeptness in optimizing resource deployment. CytoTools AG's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.023%. Furthermore, the proficiency of CytoTools AG in capital utilization is underscored by a remarkable -0.023% return on capital employed.

Stock Prices

CytoTools AG's stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $0.418, while its low point bottomed out at $0.4. This variance in figures offers investors a lucid insight into the roller-coaster ride that is CytoTools AG's stock market.

Liquidity Ratios

Analyzing T5O.DE liquidity ratios reveals its financial health of the firm. The current ratio of 2367.81% gauges short-term asset coverage for liabilities. The quick ratio (2175.40%) assesses immediate liquidity, while the cash ratio (2175.40%) indicates cash reserves.

Current Ratio2367.81%
Quick Ratio2175.40%
Cash Ratio2175.40%

Profitability Ratios

T5O.DE profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -2950.77% underscores its earnings before tax deductions. The net income per EBT, 100.00%, and the EBT per EBIT, 97.19%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -3036.07%, we grasp its operational profitability.

Pretax Profit Margin-2950.77%
Net Income per EBT100.00%
EBT per EBIT97.19%
EBIT per Revenue-3036.07%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 23.68, it details the span from stock purchase to revenue. The 22 days it takes to settle debts showcases its creditor relations.

Days of Sales Outstanding2175
Fixed Asset Turnover24.95

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -0.08, and free cash flow per share, -0.08, depict cash generation on a per-share basis. The cash per share value, 0.21, showcases liquidity position. Lastly, the operating cash flow sales ratio, -25.34, offers insight into cash flow relative to sales.

Operating Cash Flow per Share-0.08
Free Cash Flow per Share-0.08
Cash per Share0.21
Operating Cash Flow Sales Ratio-25.34
Free Cash Flow to Operating Cash Flow Ratio1.00
Capital Expenditure Coverage Ratio-231.49
Dividend Paid and Capex Coverage Ratio-231.49

Per Share Data

Net income per share, -0.17, reflects the portion of profit attributed to each share. The book value per share, 4.31, represents the net asset value distributed per share, while the tangible book value per share, 4.31, excludes intangible assets.

Net Income Per Share-0.17
Book Value Per Share4.31
Tangible Book Value Per Share4.31
Shareholders Equity Per Share4.31
Interest Debt Per Share0.01

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, -72.59%, indicates top-line expansion, while the gross profit growth, 102.47%, reveals profitability trends. EBIT growth, 47.56%, and operating income growth, 47.56%, offer insights into operational profitability progression. The net income growth, 79.56%, showcases bottom-line expansion, and the EPS growth, 84.16%, measures the growth in earnings per share.

Revenue Growth-72.59%
Gross Profit Growth102.47%
EBIT Growth47.56%
Operating Income Growth47.56%
Net Income Growth79.56%
EPS Growth84.16%
EPS Diluted Growth84.16%
Weighted Average Shares Growth27.54%
Weighted Average Shares Diluted Growth27.54%
Operating Cash Flow Growth41.68%
Free Cash Flow Growth46.26%
10-Year Revenue Growth per Share-91.56%
5-Year Revenue Growth per Share-94.21%
3-Year Revenue Growth per Share-75.17%
10-Year Operating CF Growth per Share55.04%
5-Year Operating CF Growth per Share66.25%
3-Year Operating CF Growth per Share26.60%
10-Year Net Income Growth per Share56.31%
5-Year Net Income Growth per Share66.88%
3-Year Net Income Growth per Share52.21%
10-Year Shareholders Equity Growth per Share19.14%
5-Year Shareholders Equity Growth per Share-13.62%
3-Year Shareholders Equity Growth per Share-11.38%
3-Year Dividend per Share Growth per Share-100.00%
Asset Growth18.29%
Book Value per Share Growth-6.01%
Debt Growth-100.00%
SGA Expenses Growth-99.35%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 3,871,176.2, captures the company's total value, considering both debt and equity. Income quality, 1.10, assesses the reliability of reported earnings.

Enterprise Value3,871,176.2
Income Quality1.10
Capex to Operating Cash Flow0.40%
Capex to Revenue-29.46%
Capex to Depreciation-68.66%
Graham Number4.03
Return on Tangible Assets-3.84%
Graham Net Net0.34
Working Capital1,909,393
Tangible Asset Value21,419,074
Net Current Asset Value1,764,573
Average Receivables43,547.5
Average Payables66,976.5
Average Inventory11,276.99
Days Sales Outstanding1328

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 0.10, and the price to book ratio, 0.10, reflect the market's valuation relative to the company's book value. The price to sales ratio, 122.46, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -4.81, and price to operating cash flows, -5.00, gauge market valuation against cash flow metrics.

Price Book Value Ratio0.10
Price to Book Ratio0.10
Price to Sales Ratio122.46
Price Cash Flow Ratio-5.00
Enterprise Value Multiple-6.23
Price Fair Value0.10
Price to Operating Cash Flow Ratio-5.00
Price to Free Cash Flows Ratio-4.81
Price to Tangible Book Ratio0.27
Enterprise Value to Sales316.45
Enterprise Value Over EBITDA-4.94
EV to Operating Cash Flow-4.25
Earnings Yield-14.53%
Free Cash Flow Yield-16.01%
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of CytoTools AG (T5O.DE) on the XETRA in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -4.293 in 2024.

What is the ticker symbol of CytoTools AG stock?

The ticker symbol of CytoTools AG stock is T5O.DE.

What is company IPO date?

IPO date of CytoTools AG is 2006-12-18.

What is company current share price?

Current share price is 0.406 EUR.

What is stock market cap today?

The market cap of stock today is 2016249.000.

What is PEG ratio in 2024?

The current 0.000 is 0.000 in 2024.

What is the number of employees in 2024?

In 2024 the company has 1.